Kiromic Biopharma Inc
Change company Symbol lookup
Select an option...
KRBP Kiromic Biopharma Inc
PRG PROG Holdings Inc
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc
PFS Provident Financial Services Inc
LPLA LPL Financial Holdings Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Kiromic BioPharma, Inc. is an artificial intelligence (AI) driven, end-to-end allogenic cell therapy company. The Company is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.

Premarket

Last Trade
Delayed
$0.25
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$0.25
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
101

10-day average volume:
58,525
101

Display:

Providers:

UpdateCancel
6 providers
November 08, 2022
SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects

Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating to possible false and misleading statements to investors concerning commercial prospects for...(PR Newswire)

October 27, 2022
Kiromic BioPharma Arranges Up to $10 Million Financing

Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND(R) artificial intelligence and data mining platform to develop cell and gene therapies with...(BusinessWire)

October 06, 2022
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

--Company is Streamlining Operations to Execute Deltacel-Aligned Development Strategy Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND(R)...(BusinessWire)

October 04, 2022
CLASS ACTION UPDATE for KRBP, NIO and TSP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / October 4, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff...(Accesswire)

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their Options

NEW YORK, NY / ACCESSWIRE / October 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of...(Accesswire)

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 4, 2022 in Kiromic Lawsuit - KRBP

New York, New York--(Newsfile Corp. - October 4, 2022) - Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.(Newsfile)

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class Action

San Francisco, California--(Newsfile Corp. - October 4, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. Relevant Period: June 25, 2021 - Feb. 2, 2022Lead Plaintiff...(Newsfile)

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ: KRBP) for violations of the federal securities laws. (PR Newswire)

KRBP FINAL DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

NEW YORK, NY / ACCESSWIRE / October 4, 2022 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ:KRBP): (i) pursuant and/or traceable to the offering documents issued in...(Accesswire)

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate

New York, New York--(Newsfile Corp. - October 4, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) and certain of...(Newsfile)

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ...(Newsfile)

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws. (PR Newswire)

October 03, 2022
Hagens Berman, National Trial Attorneys, Announces It Has Filed A Class Action Lawsuit Against Kiromic BioPharma (KRBP)

SAN FRANCISCO, CA / ACCESSWIRE / October 3, 2022 / Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ:KRBP) investors who purchased Kiromic shares to submit your losses now. Relevant Period: June 25, 2021 - Feb. 2, 2022(Accesswire)

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. With Losses of $75,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 3, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for...(Accesswire)

Kiromic Deadline Alert

New York, New York--(Newsfile Corp. - October 3, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) and reminds...(Newsfile)

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

New York, New York--(Newsfile Corp. - October 3, 2022) - Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.(Newsfile)

KRBP FINAL DEADLINE: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Application Deadline in Securities Class Action

SAN FRANCISCO, CA / ACCESSWIRE / October 3, 2022 / Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ:KRBP) investors who purchased Kiromic shares to submit your losses now. Class Period: June 25, 2021 - Aug. 13, 2021(Accesswire)

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) and certain of its officers, on behalf of a class...(BusinessWire)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. (PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.